Explanipedia

Talquetamab in relapsed refractory multiple myeloma: multi-institutional real-world study Open

Samer Al Hadidi, Anikó Szabó, Bhavesh Mohan Lal, Aishee Bag, Simon Zhen , et al. · 2025

Talquetamab is a first-in-class GPRC5DxCD3 bispecific antibody approved for heavily pretreated relapsed/refractory multiple myeloma (RRMM), and this multicenter retrospective analysis of 114 RRMM patients treated between October 2023 and J…

Real-world outcomes and toxicities of elranatamab (ELRA) in relapsed/refractory multiple myeloma: A retrospective analysis using the trinetx global health research network. Open

Syed A. Abutalib, Sharmilan Thanendrarajan, Frits van Rhee · 2025

Background: Elranatamab (ELRA), a bispecific antibody targeting BCMA and CD3, has demonstrated clinical efficacy in relapsed/refractory multiple myeloma (RRMM) with an overall response rate of 61% in the MagnerisMM-3 trial. However, real-w…

Disseminated Bartonella henselae Infection in a Patient With Relapsed/Refractory Multiple Myeloma Following Autologous Stem Cell Transplantation Open

Sanjay Muttineni, Sasya Dronavalli, Sharmilan Thanendrarajan, Frits van Rhee, Juan Carlos Rico Crescencio , et al. · 2025

Bartonella henselae is the causative agent of cat scratch disease (CSD), a zoonotic illness primarily transmitted to humans through scratches or bites from cats and, less commonly, by cat fleas or lice. While the most common present…

Equal survival for Black Americans with multiple myeloma when appropriately matched to White Americans Open

David E. Mery, Guido Tricot, Samer Al Hadidi, Yihao Zhan, Cody Ashby , et al. · 2025

Distinct interleukin-6 production in IPL and TAFRO subtypes of idiopathic multicentric Castleman disease Open

Asami Nishikori, Midori Filiz Nishimura, Yoshito Nishimura, Ryoichi Yamada, Tomoka Haratake , et al. · 2025

Idiopathic multicentric Castleman disease (iMCD) is a rare lymphoproliferative disorder characterized by systemic inflammation and lymphadenopathy. Two major clinical subtypes, idiopathic plasmacytic lymphadenopathy (iMCD-IPL) and iMCD wit…

The invisible divide: the impact of racial and geographic disparities on multiple myeloma outcomes - insights from a single-site study Open

Michael Bauer, Phillip Farmer, Joseph Su, Mario Schootman, Chenghui Li , et al. · 2025

Not available.

Healing of lytic lesions and restoration of bone health in multiple myeloma through sclerostin inhibition Open

Hayley M. Sabol, Aric Anloague, Japneet Kaur, Cecile Bustamante-Gomez, Sharmin Khan , et al. · 2025

Interferon-γ sparks inflammatory fire in Castleman disease Open

Frits van Rhee, David C. Fajgenbaum · 2025

Prognostic impact of focal lesion location and persistence in multiple myeloma: insights from serial PET/DWI imaging Open

Carolina Schinke, Leo Rasche, Cody Ashby, Rudy L. Van Hemert, Sharmilan Thanendrarajan , et al. · 2025

Multiple myeloma (MM) is a heterogeneous disease exemplified by focal lesions (FLs), densely populated nodules whose number and persistence during treatment predict poor outcome. However, the prognostic role of FL location and the relation…

International Consensus Histopathological Criteria for Subtyping Idiopathic Multicentric Castleman Disease Based on Machine Learning Analysis Open

Midori Filiz Nishimura, Tomoka Haratake, Yoshito Nishimura, Asami Nishikori, Remi Sumiyoshi , et al. · 2025

Idiopathic multicentric Castleman disease (iMCD) is a rare lymphoproliferative disorder classified into three recognized clinical subtypes—idiopathic plasmacytic lymphadenopathy (IPL), TAFRO, and NOS. Although clinical criteria are availab…

Altered mesenchymal and endothelial subsets in interstitial bone marrow and focal lesions in myeloma patients and SCID-hu mice Open

Wen Ling, Maurizio Zangari, Frits van Rhee, Bart Barlogie, Shmuel Yaccoby · 2025

In myeloma, the bone marrow (BM) stroma mediates tumor growth directly and indirectly through the alteration of BM niches. The mesenchymal and endothelial cell subsets altered in the interstitial BM and focal lesions (FLs) of patients newl…

Effect of Intravenous Immunoglobulin (IVIG) Supplementation on infection-free survival in recipients of BCMA-directed bispecific antibody therapy for multiple myeloma Open

Meera Mohan, Anikó Szabó, Heloise Cheruvalath, Anna Clennon, Vineel Bhatlapenumarthi , et al. · 2025

The main objective of this multi-institutional study is to understand the effect of primary intravenous immunoglobulin (IVIG) replacement on clinical outcomes in recipients of BCMA-directed bispecific antibody (bsAb), where infection remai…

The Involvement of PI3K–Akt Signaling in the Clinical and Pathological Findings of Idiopathic Multicentric Castleman Disease–Thrombocytopenia, Anasarca, Fever, Reticulin Fibrosis, and Organomegaly and Not Otherwise Specified Subtypes Open

Tomoka Haratake, Midori Filiz Nishimura, Asami Nishikori, Michael V. Gonzalez, Daisuke Ennishi , et al. · 2025

Idiopathic multicentric Castleman disease is a rare lymphoproliferative disorder that is clinically classified into idiopathic plasmacytic lymphadenopathy (IPL); thrombocytopenia, anasarca, fever, reticulin fibrosis, and organomegaly (TAFR…

Enhancing risk stratification and treatment decision in multiple myeloma with SKY92 gene expression profiling in real‐world data Open

Noa Biran, Binod Dhakal, Rubén Niesvizky, Suzanne Lentzsch, Divaya Bhutani , et al. · 2025

Summary Over the years, numerous prognostic markers for multiple myeloma (MM) risk classification have been identified; however, their variability can lead to inconsistent clinical interpretations. Gene expression profiling (GEP) signature…

Common connective tissue disorder and anti-cytokine autoantibodies are enriched in idiopathic multicentric castleman disease patients Open

Allan Feng, Michael V. Gonzalez, Müge Kalaycıoğlu, Xihui Yin, Melanie Mumau , et al. · 2025

Introduction Idiopathic Multicentric Castleman Disease (iMCD) is a polyclonal lymphoproliferative disorder involving cytokine storms that can lead to organ failure and death. The cause of iMCD is unknown, but some clinical evidence suggest…

Characterizing the heterogeneity of Castleman disease and oligocentric subtype: findings from the ACCELERATE registry Open

Sheila K. Pierson, Joshua D. Brandstadter, Drew A. Torigian, Adam Bagg, Mary Jo Lechowicz , et al. · 2025

Castleman disease (CD) describes a group of rare lymphoproliferative disorders that exhibit a wide range of symptomatology and degree of lymphadenopathy, particularly across the 2 forms of CD with unknown etiology, unicentric CD (UCD), and…

Prior exposure to belantamab mafodotin influences outcomes with idecabtagene vicleucel in patients with multiple myeloma Open

Bhavesh Mohan Lal, Marah Alzubi, Jawad Alrawabdeh, John D. Shaughnessy, Fenghuang Zhan , et al. · 2025

Exploring the Clinical Diversity of Castleman Disease and <span>TAFRO</span> Syndrome: A Japanese Multicenter Study on Lymph Node Distribution Patterns Open

Mizuna Otsuka, Tomohiro Koga, Remi Sumiyoshi, Shoichi Fukui, Yuko Kaneko , et al. · 2025

Individuals diagnosed with Castleman disease (CD) and TAFRO syndrome (characterized by thrombocytopenia, anasarca, fever, bone marrow fibrosis, and organomegaly) displays a wide range of clinical symptoms, including varying patterns of lym…

Idiopathic Multicentric Castleman Disease: Still a Diagnostic Conundrum? Open

Frits van Rhee · 2025

Long-term follow-up of Total Therapy IV: a phase 3 clinical trial for standard-risk multiple myeloma Open

Samer Al Hadidi, Obada Ababneh, Carolina Schinke, Sharmilan Thanendrarajan, Clyde Bailey , et al. · 2024

Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages Open

Yan Cheng, Fumou Sun, Daisy Alapat, Visanu Wanchai, David E. Mery , et al. · 2024

Psychological Impact in Individuals with Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma Open

Tanvi H Patel, Ramya Bachu, Trilok Shrivastava, Jawad Alrawabdeh, Marah Alzubi , et al. · 2024

In our study of 246 newly diagnosed individuals with MGUS or SMM (115 MGUS, 131 SMM), we found that 19% reported anxiety, with no significant difference between the MGUS and SMM groups (22% vs. 17%). Those with a history of psychiatric dis…

Second primary malignancies after tandem autologous hematopoietic stem cell transplantation for multiple myeloma Open

Samer Al Hadidi, Obada Ababneh, Carolina Schinke, Sharmilan Thanendrarajan, Clyde Bailey , et al. · 2024

Autologous hematopoietic stem cell transplantation (HSCT) is a standard treatment for eligible multiple myeloma (MM) patients.1 Before high-dose chemotherapy and autologous HSCT, patients typically receive induction therapy with a proteaso…

Deciphering the genetics and mechanisms of predisposition to multiple myeloma Open

Molly Went, Laura Duran-Lozano, Gísli H. Halldórsson, Andrea Gunnell, Nerea Ugidos-Damboriena , et al. · 2024

Weight loss and dysgeusia in relapsed/refractory multiple myeloma patients treated with talquetamab Open

Syed Naqvi, Asis Shrestha, Marah Alzubi, Jawad Alrawabdeh, Sharmilan Thanendrarajan , et al. · 2024

Talquetamab is an approved therapy for relapsed multiple myeloma. This study examined dysgeusia and weight loss occurrences, alongside investigating symptom reversibility post‐treatment cessation. Dysgeusia was prevalent, persisting in 15%…

Insights into the etiology of Castleman disease Open

Frits van Rhee, David C. Fajgenbaum · 2024

In this issue of Blood, Chan et al report on in-depth studies of identical twins with idiopathic multicentric Castleman disease (iMCD), which provides a unique opportunity to study a genetic background for this enigmatic disorder. 1Chan et…

B‐cell maturation antigen‐based therapies post‐talquetamab in relapsed or refractory multiple myeloma Open

Asis Shrestha, Marah Alzubi, Jawad Alrawabdeh, Carolina Schinke, Sharmilan Thanendrarajan , et al. · 2024

Talquetamab recently received approval for relapsed refractory multiple myeloma. However, there is currently no available data on how patients perform with BCMA based agents after progression on talquetamab. Herein, we present the outcome …

A meta-analysis of genome-wide association studies of multiple myeloma among men and women of African ancestry Open

Zong‐Jun Du, Niels Weinhold, Song Gao, K.A. Rand, David Van Den Berg , et al. · 2024

Persons of African ancestry (AA) have a twofold higher risk for multiple myeloma (MM) compared with persons of European ancestry (EA). Genome-wide association studies (GWASs) support a genetic contribution to MM etiology in individuals of …

A Risk Stratification System in Myeloma Patients with Autologous Stem Cell Transplantation Open

Wancheng Guo, Christopher Strouse, David E. Mery, Eric R. Siegel, Manit Munshi , et al. · 2024

Autologous stem cell transplantation (ASCT) has been a mainstay in myeloma treatment for over three decades, but patient prognosis post-ASCT varies significantly. In a retrospective study of 5259 patients with multiple myeloma (MM) at the …

Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study Open

Meera Mohan, Jorge Monge, Nishi Shah, Danny Luan, Mark Forsberg , et al. · 2024

The objective of our study was to report real-world data on the safety and efficacy of standard-of-care teclistamab in patients with relapsed/refractory multiple myeloma (MM). This is a multi-institutional retrospective cohort study and in…

Frits van Rhee YOU? Author Swipe